Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

A randomized trial comparing ibrutinib plus rituximab with rituximab alone in patients with Waldenström’s macroglobulinemia showed significantly higher rates of progression-free survival and overall response with the addition of ibrutinib.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 378; no. 25; pp. 2399 - 2410
Main Authors Dimopoulos, Meletios A, Tedeschi, Alessandra, Trotman, Judith, García-Sanz, Ramón, Macdonald, David, Leblond, Veronique, Mahe, Beatrice, Herbaux, Charles, Tam, Constantine, Orsucci, Lorella, Palomba, M. Lia, Matous, Jeffrey V, Shustik, Chaim, Kastritis, Efstathios, Treon, Steven P, Li, Jianling, Salman, Zeena, Graef, Thorsten, Buske, Christian
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 21.06.2018
Subjects
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Arthralgia
Atrial Fibrillation - chemically induced
B-cell lymphoma
Bone marrow
Cancer
CXCR4 protein
Diarrhea
Disease-Free Survival
Female
Fibrillation
Hemoglobin
Hemoglobins - analysis
Hemorrhage
Hospitals
Humans
Hypertension
Immunoglobulin M
Immunoglobulin M - blood
Immunotherapy
Infusions, Intravenous - adverse effects
Inhibitor drugs
Lymphocytes B
Macroglobulinemia
Male
Medical research
Middle Aged
Monoclonal antibodies
MyD88 protein
Nausea
Patients
Pyrazoles - administration & dosage
Pyrazoles - adverse effects
Pyrimidines - administration & dosage
Pyrimidines - adverse effects
R&D
Research & development
Response rates
Rituximab
Rituximab - administration & dosage
Rituximab - adverse effects
Survival Analysis
Targeted cancer therapy
Waldenstrom Macroglobulinemia - blood
Waldenstrom Macroglobulinemia - drug therapy
Online AccessGet full text

Cover

More Information
Summary:A randomized trial comparing ibrutinib plus rituximab with rituximab alone in patients with Waldenström’s macroglobulinemia showed significantly higher rates of progression-free survival and overall response with the addition of ibrutinib.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1802917